Simvastatin overcomes the resistance to serum withdrawal-induced apoptosis of lymphocytes from Alzheimer's disease patients

Cellular and Molecular Life Sciences

Volumn 67, Issue 24, 2010, Pages 4257-4268

  Bartolomé, Fernando ^a   Muñoz, Úrsula ^a,e   Esteras, Noemí ^a   Alquezar, Carolina ^a,d   Collado, Andrea ^a   Bermejo Pareja, Felix ^b,c   Martín Requero, Ángeles ^a,d  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; ERK1 2; Lymphocytes; P21; PI3K Akt; Simvastatin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIMVASTATIN;

AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TARGETING; ENZYME REGULATION; FEMALE; HUMAN; LYMPHOBLAST; LYMPHOCYTE; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; SIGNAL TRANSDUCTION; TARGET CELL;

AGED; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTES; MALE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SERUM; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 78651295008     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0443-2     Document Type: Article

References (66)

1. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
2. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269
3. Corsini A, Maggi FM, Catapano AL (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31:9-27
4. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118
5. Farnier M, Davignon J (1998) Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82:3J-10J
6. Gotto AM Jr, Kuller LH (2002) Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare? Circulation 105:136-139
7. Laufs U, Liao JK (2000) Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10:143-148
8. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185:63-70
9. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C (2008) Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5:416-421
10. Shobab LA, Hsiung GY, Feldman HH (2005) Cholesterol in Alzheimer's disease. Lancet Neurol 4:841-852
11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
12. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59:378-384
13. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F (2010) Statins and cognitive functioning in the elderly: a populationbased study. J Alzheimers Dis
14. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2:343-353
15. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74:956-964
16. Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE, Wood WG (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 35:251-257
17. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282:26832-26844
18. Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A (2009) Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol 63:997-1005
19. Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ Jr, Borch RF, Mattingly RR (2008) Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 326:1-11
20. Herrup K, Neve R, Ackerman SL, Copani A (2004) Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 24:9232-9239
21. Nagy Z (2005) The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med 9:531-541
22. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T (2007) Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci 27:6859-6867
23. Yang Y, Geldmacher DS, Herrup K (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21:2661-2668
24. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, Linford NJ, Funk JO, Shapiro RA, Smith MA (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772:467-472
25. Xu SQ, El-Deiry WS (2000) p21 (WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269:179-190
26. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, Roninson IB (2000) Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA 97:4291-4296
27. Zhu X, McShea A, Harris PL, Raina AK, Castellani RJ, Funk JO, Shah S, Atwood C, Bowen R, Bowser R, Morelli L, Perry G, Smith MA (2004) Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res 75:698-703
28. 2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol Dis 13:254-263
29. Nagy Z, Combrinck M, Budge M, McShane R (2002) Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett 317:81-84
30. Tatebayashi Y, Takeda M, Kashiwagi Y, Okochi M, Kurumadani T, Sekiyama A, Kanayama G, Hariguchi S, Nishimura T (1995) Cell-cycle-dependent abnormal calcium response in fibroblasts from patients with familial Alzheimer's disease. Dementia 6:9-16
31. Urcelay E, Ibarreta D, Parrilla R, Ayuso MS, Martin-Requero A (2001) Enhanced proliferation of lymphoblasts from patients with Alzheimer dementia associated with calmodulin-dependent activation of the na+/H+ exchanger. Neurobiol Dis 8:289-298
32. Sala SG, Munoz U, Bartolome F, Bermejo F, Martin-Requero A (2008) HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther 324:352-359
33. 2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci 64:1437-1448
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
35. Ibarreta D, Urcelay E, Parrilla R, Ayuso MS (1998) Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients. Ann Neurol 44:216-222
36. Koistinen P (1987) Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases. Scand J Clin Lab Invest 47:709-714
37. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
38. de las Cuevas N, Munoz U, Hermida OG, Martin-Requero A (2005) Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol Aging 26:615-624
39. Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111:293-303
40. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912
41. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689
42. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248
43. Munoz U, Bartolome F, Bermejo F, Martin-Requero A (2008) Enhanced proteasome-dependent degradation of the CDK inhibitor p27 (kip1) in immortalized lymphocytes from Alzheimer's dementia patients. Neurobiol Aging 29:1474-1484
44. Bartolome F, Munoz U, Esteras N, Esteban J, Bermejo-Pareja F, Martin-Requero A (2009) Distinct regulation of cell cycle and survival in lymphocytes from patients with Alzheimer's disease and amyotrophic lateral sclerosis. Int J Clin Exp Pathol 2:390-398
45. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3:219-226
46. Naderi J, Lopez C, Pandey S (2006) Chronically increased oxidative stress in fibroblasts from Alzheimer's disease patients causes early senescence and renders resistance to apoptosis by oxidative stress. Mech Ageing Dev 127:25-35
47. Eckert A, Oster M, Zerfass R, Hennerici M, Muller WE (2001) Elevated levels of fragmented DNA nucleosomes in native and activated lymphocytes indicate an enhanced sensitivity to apoptosis in sporadic Alzheimer's disease. Specific differences to vascular dementia. Dement Geriatr Cogn Disord 12:98-105
48. Morocz M, Kalman J, Juhasz A, Sinko I, McGlynn AP, Downes CS, Janka Z, Rasko I (2002) Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 23:47-53
49. Uberti D, Carsana T, Bernardi E, Rodella L, Grigolato P, Lanni C, Racchi M, Govoni S, Memo M (2002) Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J Cell Sci 115:3131-3138
50. Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65:3980-3985
51. Kim DK, Cho ES, Lee SJ, Um HD (2001) Constitutive hyperexpression of p21 (WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas. Biochem Biophys Res Commun 289:34-38
52. Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W (1998) Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1, 3-bis (2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 58:1538-1543
53. Weiss RH (2003) p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425-429
54. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362-1371
55. Gauthaman K, Manasi N, Bongso A (2009) Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157:962-973
56. Fonseca AC, Proenca T, Resende R, Oliveira CR, Pereira CM (2009) Neuroprotective effects of statins in an in vitro model of Alzheimer's disease. J Alzheimers Dis 17:503-517
57. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG (2007) Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem 101:77-86
58. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104-11111
59. Franke C, Noldner M, Abdel-Kader R, Johnson-Anuna LN, Gibson Wood W, Muller WE, Eckert GP (2007) Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 25:438-445
60. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M (1998) Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17:931-939
61. Helt CE, Rancourt RC, Staversky RJ, O'Reilly MA (2001) p53-dependent induction of p21 (Cip1/WAF1/Sdi1) protects against oxygen-induced toxicity. Toxicol Sci 63:214-222
62. Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G (2001) Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci Lett 303:79-82
63. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223-1234
64. Knowles RB, Chin J, Ruff CT, Hyman BT (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer disease. J Neuropathol Exp Neurol 58:1090-1098
65. McShea A, Zelasko DA, Gerst JL, Smith MA (1999) Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Res 815:237-242
66. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF (2004) Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15:955-959